BROADER
HEALTH
BENEFITS

Viral suppression with oral ART was the first step, now it’s time to take your patients further

With 6 doses per year, following initiation,[1,2] 2-monthly VOCABRIA + REKAMBYS enables people living with HIV the opportunity to thrive through high adherence and treatment satisfaction vs. regular daily orals[3-8]

There are additional considerations for long-term health where VOCABRIA + REKAMBYS may support people living with HIV

VOCABRIA + REKAMBYS offers:

Reduced drug exposure vs 3-drug regimens

and is TDF, TAF and ABC free[1,2]

Low potential for drug-drug interactions

with an established interaction profile[1,2]

Neutral impact

on renal, bone and metabolic health[9,10]

In the SOLAR clinical trial:

Bone health

No clinically significant changes were observed in bone biomarkers from baseline to Month 12.[9]

Renal health

Minimal changes were observed across multiple renal biomarkers between baseline and Month 12.[9]

Metabolic health

VOCABRIA + REKAMBYS had a neutral impact on weight, insulin resistance, and metabolic syndrome from baseline to Month 12.[10]

The SOLAR primary endpoint was met: 2-monthly VOCABRIA + REKAMBYS was non-inferior to BIC/FTC/TAF at Month 12 (mITT-E: 1% [n=5/447] with plasma HIV-1 RNA ≥50 copies/mL vs 0.4% [n=1/223], respectively; adjusted difference = 0.7% [95% CI: -0.7%, 2.0%]; 4% non-inferiority margin).[3]

Involvement in treatment decisions and satisfaction with care empowers people living with HIV to take charge of their own health, adhere to treatment and remain in care[11,12]

Explore how VOCABRIA + REKAMBYS may benefit people living with HIV, beyond viral suppression:

Patient preference

Read more

Adherence and retention in care

Read more

Treatment satisfaction

Read more

Explore safety and tolerability information

Contact us for support

ABC=abacavir; ART=antiretroviral therapy; HIV=human immunodeficiency virus; HIV-1=human immunodeficiency virus type 1; mITT-E=modified intention-to-treat exposed; RNA=ribonucleic acid; TAF=tenofovir alafenamide; TDF=tenofovir disoproxil fumarate.

References:

  1. VOCABRIA (cabotegravir) 600 mg suspension for injection Summary of Product Characteristics (SmPC).
  2. REKAMBYS (rilpivirine) 900 mg suspension for injection Summary of Product Characteristics (SmPC).
  3. Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10(9):e566–e577. doi: 10.1016/S2352-3018(23)00136-4.
  4. Wyen C, Noe S, Jonsson-Oldenbüttel C, et al. 24-Month Outcomes of Cabotegravir Plus Rilpivirine Long-Acting Every 2 Months in a Real-World Setting: Effectiveness, Adherence to Injections, and Patient-Reported Outcomes From People With HIV-1 in the German CARLOS Study. Presented at: The 13th International AIDS Society (IAS) Conference; July 13–17, 2025; Kigali, Rwanda. Poster TUPEB035.
  5. Kityo C, Mambule IK, Sokhela S, et al. Randomized trial of Cabotegravir and Rilpivirine Long-acting in Africa (CARES): Week 96 Results. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); March 9–12, 2025; San Francisco, California, USA. Oral abstract 00202.
  6. Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomized, multicentre, open-label, phase 3b, non-inferiority study. Published in Lancet. 2021; Vol. 396, Issue 10267, Pages 1994–2005. DOI: 10.1016/S0140-6736(20)32666-0.
  7. Muccini C, Capra N, Lolatto R, et al. Two-years efficacy and safety of long-acting cabotegravir and rilpivirine in the SChoLART study. Presented at: The Italian Conference on AIDS and Antiviral Research (ICAR); May 21–23, 2025; Padua, Italy. Oral presentation 0C35.
  8. John M, Williams L, Nolan G, et al. Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the injectable Antiretroviral therapy feasibility study (JABS). Published in HIV Medicine. 2024; Vol. 25, Issue 8, Pages 935–945. DOI: 10.1111/hiv.13647.
  9. Sutton K, Gomis SC, Giacomelli A, et al. Renal and Bone Biomarker Outcomes After Cabotegravir + Rilpivirine Long-Acting in the Phase 3b SOLAR Study. Presented at: 25th International Workshop on Long-term Complications of HIV and SARS-CoV-2; December 14–15, 2023; Washington, DC, USA. Poster ADRLH-44.
  10. Tan DHS, Antinori A, Eu B, et al. Weight and Metabolic Changes With Long-Acting Cabotegravir and Rilpivirine or Bictegravir/Emtricitabine/Tenofovir Alafenamide. J Acquir Immune Defic Syndr. 2025;98(4):401-409. doi: 10.1097/QAI.0000000000003584.
  11. Okoli C, Brough G, Allan B, et al. Shared Decision Making Between Patients and Healthcare Providers and its Association with Favorable Health Outcomes Among People Living with HIV. AIDS Behav. 2021;25(5):1384–1395. doi: 10.1007/s10461-020-02973-4.
  12. Keelson SA, Addo JO, Amoah J. The impact of patient engagement on service quality and customer well-being: an introspective analysis from the healthcare providers’ perspective. Cogent Public Health. 2024;11(1):2340157. doi: 10.1080/27707571.2024.2340157.

REKAMBYS (rilpivirine long-acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned or licensed by the ViiV Healthcare group. ©2025 ViiV Healthcare group of companies or its licensor. All rights reserved.

PM-GB-CBR-WCNT-250010 | March 2026

Prescribing Information

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.